Broadwing Bio

Executive Summary

Broadwing Bio is a private biotechnology company founded in 2021 and headquartered in Cambridge, USA, dedicated to developing antibody-based therapies for major causes of adult vision loss. The company leverages a genetics-driven approach to target validated pathways underlying Geographic Atrophy (GA) and Glaucoma, two leading causes of irreversible blindness. By focusing on genetically supported targets, Broadwing aims to improve the probability of clinical success and address significant unmet medical needs in ophthalmology. While the company is still in early stages, its precision medicine strategy and experienced team position it well within the competitive landscape. The initial pipeline remains undisclosed, but progress toward IND-enabling studies is expected in the near term.

Upcoming Catalysts (preview)

• Q3 2026Lead Program IND Filing for GA40% success
• Q4 2026Preclinical Proof-of-Concept Data for Glaucoma Program50% success
• Q4 2026Partnership or Licensing Deal for Antibody Platform30% success